Sangamo Therapeutics Inc Financials
Sangamo Therapeutics Inc (SGMO) reported $34.6M in revenue over the twelve months to Mar 31, 2026, down 45.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
External financing, not commercial revenue, is carrying this development-stage business as its cash base shrinks.
By FY2025, cash burn of-$97.2M sat far above year-end cash of$20.9M , so the company finished the year reliant on fresh capital rather than reserves. That dependence shows up in the balance sheet too: equity turned negative and the current ratio slipped below 1.0x, meaning financing is now supporting both research spending and near-term liquidity.
The operating model still looks like a capital-consuming research platform: R&D remained
Revenue fell from
Financial Health Signals
We are recalculating Sangamo Therapeutics Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
Sangamo Therapeutics Inc scores -44.05, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($30.7M) relative to total liabilities ($74.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Sangamo Therapeutics Inc passes 2 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
Sangamo Therapeutics Inc reported a net loss of $122.9M while operations used $97.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Sangamo Therapeutics Inc generated $39.6M in revenue in fiscal year 2025. This represents a decrease of 31.6% from the prior year.
Sangamo Therapeutics Inc's EBITDA was -$117.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.6% from the prior year.
Sangamo Therapeutics Inc reported -$122.9M in net income in fiscal year 2025. This represents a decrease of 25.5% from the prior year.
Sangamo Therapeutics Inc earned -$0.44 per diluted share (EPS) in fiscal year 2025. This represents an increase of 10.2% from the prior year.
Cash & Balance Sheet
Sangamo Therapeutics Inc recorded an outflow of $97.3M in free cash flow in fiscal year 2025, representing a cash shortfall after capex. This represents a decrease of 44.4% from the prior year.
Sangamo Therapeutics Inc held $20.9M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Margins & Returns
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2025.
Capital Allocation
Sangamo Therapeutics Inc invested $112.7M in research and development in fiscal year 2025. This represents an increase of 1.0% from the prior year.
Sangamo Therapeutics Inc invested $102K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 61.8% from the prior year.
Not reported for fiscal year 2025.
SGMO Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4M-89.9% | $14.2M+2348.9% | $581K-96.8% | $18.3M+184.4% | $6.4M-14.8% | $7.6M-84.7% | $49.4M+13779.8% | $356K |
| R&D Expenses | $26.6M-15.5% | $31.4M+11.7% | $28.1M+3.9% | $27.1M+4.1% | $26.0M+9.8% | $23.7M-14.6% | $27.7M+14.5% | $24.2M |
| SG&A Expenses | $6.8M-12.1% | $7.8M-2.9% | $8.0M-12.0% | $9.1M-9.8% | $10.1M+2.0% | $9.9M-10.7% | $11.0M-8.3% | $12.0M |
| Operating Income | -$31.9M+16.4% | -$38.2M-7.5% | -$35.6M-99.1% | -$17.9M+39.7% | -$29.6M-14.0% | -$26.0M-344.5% | $10.6M+128.7% | -$37.1M |
| Income Tax | $0+100.0% | -$553K-243.5% | -$161K-696.3% | $27K-77.3% | $119K+127.9% | -$427K-585.2% | $88K+18.9% | $74K |
| Net Income | -$31.0M+17.2% | -$37.4M-7.1% | -$34.9M-74.8% | -$20.0M+34.7% | -$30.6M-30.8% | -$23.4M-319.2% | $10.7M+129.5% | -$36.1M |
| EPS (Diluted) | -$0.08 | N/A | -$0.11-37.5% | -$0.08+42.9% | -$0.14 | N/A | $0.04+122.2% | -$0.18 |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, Interest Expense.
SGMO Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $60.0M+0.4% | $59.7M-32.6% | $88.6M-9.1% | $97.6M+13.2% | $86.2M-15.2% | $101.6M-8.7% | $111.3M+19.6% | $93.0M |
| Current Assets | $37.1M+3.6% | $35.8M-18.7% | $44.1M-11.7% | $49.9M+32.7% | $37.6M-27.3% | $51.7M-11.1% | $58.1M+45.1% | $40.1M |
| Cash & Equivalents | $27.6M+31.7% | $20.9M-29.3% | $29.6M-22.8% | $38.3M+52.3% | $25.2M-39.9% | $41.9M+6.9% | $39.2M+41.1% | $27.8M |
| Accounts Receivable | $873K+135.3% | $371K-29.1% | $523K+40.6% | $372K+1.6% | $366K-30.4% | $526K-95.0% | $10.5M+1706.5% | $581K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | $0 | N/A | N/A |
| Total Liabilities | $78.9M+6.6% | $74.0M-10.2% | $82.4M+5.7% | $78.0M-4.1% | $81.3M+3.0% | $78.9M+9.3% | $72.1M+4.0% | $69.3M |
| Current Liabilities | $53.1M+25.1% | $42.5M-15.3% | $50.1M+5.2% | $47.7M-3.8% | $49.6M+8.2% | $45.8M+6.1% | $43.2M+10.7% | $39.0M |
| Total Equity | -$19.0M-32.8% | -$14.3M-328.5% | $6.2M-68.2% | $19.6M+299.6% | $4.9M-78.5% | $22.8M-41.8% | $39.1M+65.2% | $23.7M |
| Retained Earnings | -$1.7B-1.9% | -$1.6B-2.4% | -$1.6B-2.2% | -$1.6B-1.3% | -$1.5B-2.0% | -$1.5B-1.6% | -$1.5B+0.7% | -$1.5B |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
SGMO Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$19.3M+21.0% | -$24.4M+14.4% | -$28.5M-56.9% | -$18.2M+30.6% | -$26.1M-680.3% | -$3.4M-128.5% | $11.8M+143.7% | -$26.9M |
| Capital Expenditures | $13K-7.1% | $14K-78.1% | $64K+166.7% | $24K | $0-100.0% | $152K+32.2% | $115K | $0 |
| Free Cash Flow | -$19.3M+21.0% | -$24.4M+14.5% | -$28.6M-57.1% | -$18.2M+30.5% | -$26.1M-646.5% | -$3.5M-130.1% | $11.6M+143.3% | -$26.9M |
| Investing Cash Flow | -$13K+7.1% | -$14K+78.1% | -$64K-166.7% | -$24K | $0-100.0% | $1.3M+468.2% | $233K+83.5% | $127K |
| Financing Cash Flow | $26.7M+80.4% | $14.8M-22.9% | $19.2M-32.9% | $28.6M+251.8% | $8.1M+16.3% | $7.0M+3543.8% | -$203K+61.9% | -$533K |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
SGMO Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -2215.4% | -268.5% | -6119.3% | -97.5% | -460.3% | -344.2% | 21.5% | -10416.8% |
| Net Margin | -2149.4% | -263.0% | -6012.1% | -109.2% | -475.3% | -309.8% | 21.6% | -10148.3% |
| Return on Equity | N/A | N/A | -559.5%-457.6pp | -102.0%+521.7pp | -623.7%-520.9pp | -102.7%-130.0pp | 27.3%+179.8pp | -152.5% |
| Return on Assets | -51.7%+10.9pp | -62.6%-23.2pp | -39.4%-18.9pp | -20.5%+15.0pp | -35.5%-12.5pp | -23.0%-32.6pp | 9.6%+48.4pp | -38.8% |
| Current Ratio | 0.70-0.1x | 0.840.0x | 0.88-0.2x | 1.05+0.3x | 0.76-0.4x | 1.13-0.2x | 1.35+0.3x | 1.03 |
| Debt-to-Equity | N/A | N/A | 13.20+9.2x | 3.98-12.6x | 16.56+13.1x | 3.46+1.6x | 1.84-1.1x | 2.93 |
| FCF Margin | -1338.1% | -171.6% | -4916.0% | -99.3% | -406.2% | -46.4%-70.0pp | 23.6% | -7551.7% |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$14.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.84), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Sangamo Therapeutics Inc Ranks
Frequently Asked Questions
What is Sangamo Therapeutics Inc's annual revenue?
Sangamo Therapeutics Inc (SGMO) reported $39.6M in total revenue for fiscal year 2025. This represents a -31.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Sangamo Therapeutics Inc's revenue growing?
Sangamo Therapeutics Inc (SGMO) revenue declined by 31.6% year-over-year, from $57.8M to $39.6M in fiscal year 2025.
Is Sangamo Therapeutics Inc profitable?
No, Sangamo Therapeutics Inc (SGMO) reported a net income of -$122.9M in fiscal year 2025.
What is Sangamo Therapeutics Inc's EBITDA?
Sangamo Therapeutics Inc (SGMO) had EBITDA of -$117.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Sangamo Therapeutics Inc's free cash flow?
Sangamo Therapeutics Inc (SGMO) recorded an outflow of $97.3M in free cash flow during fiscal year 2025. This represents a -44.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Sangamo Therapeutics Inc's operating cash flow?
Sangamo Therapeutics Inc (SGMO) recorded an outflow of $97.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Sangamo Therapeutics Inc's total assets?
Sangamo Therapeutics Inc (SGMO) had $59.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Sangamo Therapeutics Inc's capital expenditures?
Sangamo Therapeutics Inc (SGMO) invested $102K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Sangamo Therapeutics Inc spend on research and development?
Sangamo Therapeutics Inc (SGMO) invested $112.7M in research and development during fiscal year 2025.
What is Sangamo Therapeutics Inc's current ratio?
Sangamo Therapeutics Inc (SGMO) had a current ratio of 0.84 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Sangamo Therapeutics Inc's return on assets (ROA)?
Sangamo Therapeutics Inc (SGMO) had a return on assets of -205.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Sangamo Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Sangamo Therapeutics Inc (SGMO) held $20.9M in cash, cash equivalents and investments, and reported an operating cash outflow of $97.2M over that year. Dividing the one by the other, the reported balance equals about 3 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Why is Sangamo Therapeutics Inc's debt-to-equity ratio negative or not reported?
Sangamo Therapeutics Inc (SGMO) has negative shareholder equity of -$14.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Sangamo Therapeutics Inc's Altman Z-Score?
Sangamo Therapeutics Inc (SGMO) has an Altman Z-Score of -44.05, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Sangamo Therapeutics Inc's Piotroski F-Score?
Sangamo Therapeutics Inc (SGMO) has a Piotroski F-Score of 2 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Sangamo Therapeutics Inc's earnings high quality?
Sangamo Therapeutics Inc (SGMO) reported a net loss of $122.9M while operations used $97.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.